| Literature DB >> 24768347 |
Emilia Falkowska1, Khoa M Le2, Alejandra Ramos3, Katie J Doores4, Jeong Hyun Lee5, Claudia Blattner5, Alejandro Ramirez6, Ronald Derking7, Marit J van Gils7, Chi-Hui Liang2, Ryan Mcbride8, Benjamin von Bredow9, Sachin S Shivatare10, Chung-Yi Wu10, Po-Ying Chan-Hui11, Yan Liu12, Ten Feizi12, Michael B Zwick6, Wayne C Koff13, Michael S Seaman14, Kristine Swiderek11, John P Moore15, David Evans9, James C Paulson16, Chi-Huey Wong10, Andrew B Ward5, Ian A Wilson17, Rogier W Sanders18, Pascal Poignard3, Dennis R Burton19.
Abstract
Broadly neutralizing HIV antibodies are much sought after (a) to guide vaccine design, both as templates and as indicators of the authenticity of vaccine candidates, (b) to assist in structural studies, and (c) to serve as potential therapeutics. However, the number of targets on the viral envelope spike for such antibodies has been limited. Here, we describe a set of human monoclonal antibodies that define what is, to the best of our knowledge, a previously undefined target on HIV Env. The antibodies recognize a glycan-dependent epitope on the prefusion conformation of gp41 and unambiguously distinguish cleaved from uncleaved Env trimers, an important property given increasing evidence that cleavage is required for vaccine candidates that seek to mimic the functional HIV envelope spike. The availability of this set of antibodies expands the number of vaccine targets on HIV and provides reagents to characterize the native envelope spike.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24768347 PMCID: PMC4070425 DOI: 10.1016/j.immuni.2014.04.009
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745